Dataset from A Phase 2 Multicenter Open-label Study Evaluating the Safety and Efficacy of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA)

This is a multicenter phase 2 open-label single-arm study that will evaluate the safety and
efficacy of TAK-700 in patients with castration-resistant prostate cancer (CRPC) without
radiographic evidence of metastases who have a rising prostate-specific antigen (PSA).